Innovent’s Partner Ollin Reports on the Clinical Study of IBI324

Image Credits: Innovent Biologics

Announcement

Innovent Biologics Inc., a leading biopharmaceutical company that establishes commercialization and manufacturing of high-quality medicines for the treatment of autoimmune, metabolic, cardiovascular, and oncology, ophthalmology, and other crucial disease areas, informed of the updates brought by the company’s partner Ollin regarding the clinical study IBI324 (Ollin R&D code: OLN324). The IBI324 (OLN324) is a potential higher molar dose VEGF/Ang2 bispecific antibody in phase 1b clinical development for diabetic macular edema (DME) or wet (neovascular) age-based macular degeneration (WAMD), the leading causes of vision loss in working-age and older individuals. The ollin has completed the enrollment process of around 150 patients with DME and WAMD in the JADE study. A JADE study is a US-based phase 1b proof-of-concept clinical trial engineered to examine OLN324 versus faricimab for competent areas of durability and anatomic differentiation. The highlighted results from the study are predicted in the first quarter of 2026.

Formed on the evidence-based strong efficacy of anti-VEGF, OLN324’s exponentially highest anti-ang2 potency over the recent market leader, faricimab, aligned with the smaller protein format position OLN324 as a capable medication for the best-in-class disease control. The OLN324 is examined at the highest molar doses in comparison to faricimab’s testing frequency to achieve greater focus coverage and the capability for expanded treatment durability. These all feature rank OLN324as an eligible candidate for the first line, differentiated standard of care profile.

Views and Statements from the Company Leaders

The MD, Phd, chairman of research, Retina Consultants of America, and member of Ollin’s scientific advisory board, Charles C. Wykoff said, “The ang2 and VEGF play a crucial role in the vascular pathologies that fuel DME and WAMD. The dual focus can enhance the anatomic outcomes and gain more durable disease control as compared to VEGF inhibition alone. The take on the first US FDA-approved VEGF/Ang2 inhibitor, faricimab, shows the interest from patients and retinal specialists for new medicines providing enhanced outcomes by focusing on multiple drivers of disease. There is a meaningful space for clinical improvement for patients. Ollin’s phase 1b study discovers the ability for differentiation of OLN324 versus faricimab from the outset.”

Chief R&D officer of General Biomedicine from Innovent Biologics, Dr. Lei Qian, said, “We are thrilled about the success of the OLN324 (IBI324), supported by our partner ollin mainly the successful enrollment completion of the JADE phase 1b trial, which shows a major milestone signalling both parties' strong partnership.”